LTRN | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.46%

1 Month

0.37%

3 Months

-25.00%

6 Months

-29.50%

1 Year

-29.69%

2 Year

-64.94%

Key data

Stock price

$2.70

P/E Ratio

0.00

DAY RANGE

$2.60 - $2.75

EPS

-$1.77

52 WEEK RANGE

$2.45 - $5.74

52 WEEK CHANGE

-$27.81

MARKET CAP

46.977 M

YIELD

N/A

SHARES OUTSTANDING

11.184 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.73

PUBLIC FLOAT

AVERAGE 10 VOLUME

$28,228

AVERAGE 30 VOLUME

$48,675

Company detail

CEO: Panna L. Sharma
Region: US
Website: lanternpharma.com
Employees: 20
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN - Lantern Pharma Inc